Novartis shares are trading significantly higher than those of rival Roche, reflecting investor confidence in the Swiss pharmaceutical giant's ability to navigate patent expirations and sustain growth.
The divergence in market performance highlights a broader shift in sentiment toward companies demonstrating resilience in their core portfolios despite headwinds from off-patent blockbusters.
The market's preference for Novartis comes as the company continues to offset substantial revenue declines from its flagship heart medication, Entresto, which has lost patent protection.
Strong sales in oncology and multiple sclerosis have bolstered Novartis' second-quarter core operating profit, exceeding analyst expectations and reinforcing the view that the company's pipeline is effectively replacing lost revenue streams.
Meanwhile, the wider Swiss pharmaceutical sector is bracing for a period of intense consolidation.
Industry observers note that an unprecedented number of biotech firms are expected to change hands this year, driven by major pharma companies' urgent need to replenish their product portfolios.